Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hydroxyurea was found to be a good treatment in adult patients with sickle cell anemia with significant decrease in the frequency of vaso-occlusive crises and other crises related to SCA. Several studies were published with relative short term follow up in pediatric and young adult age. The purpose of this study is to assess the long term follow up in a group of patients that initiated Hydroxyurea treatment in childhood.
| Condition | Intervention |
|---|---|
|
Sickle Cell Anemia Sickle Cell Thalassemia |
Other: Clinical follow up and laboratory analysis |
| Study Type: | Observational |
| Study Design: | Observational Model: Case-Only Time Perspective: Retrospective |
| Official Title: | Long Term Follow up in Sickle Cell Patients Treated by Hydroxyurea.Observational Retrospective Study. |
| Estimated Enrollment: | 20 |
| Study Start Date: | May 2007 |
| Study Completion Date: | December 2008 |
| Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
Patients with Sickle cell anemia treated by Hydroxyurea
|
Other: Clinical follow up and laboratory analysis
Clinical follow up and laboratory analysis
|
Detailed Description:
Hydroxyurea was found to be a good treatment in adult patients with sickle cell anemia with significant decrease in the frequency of vaso-occlusive crises and other crises related to SCA. Several studies were published with relative short term follow up in pediatric and young adult age. The purpose of this study is to assess the long term follow up in a group of patients that initiated Hydroxyurea treatment in childhood.
A long term follow up will be recorded in a cohort of twenty SCA patients treated by Hydroxyurea for a period between 5 to 12 years. The frequency of vaso-occlusive crises, acute chest syndrome, blood transfusions, and hospitalization will be recorded retrospectively. Also the mean hgb level and hgb F percentage will be summarized.
Eligibility| Ages Eligible for Study: | 5 Years to 40 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with Sickle Cell Anemia treated at the Pediatric Hematology Unit and receiving Hydroxyurea
Inclusion Criteria:
- All patients treated by Hydroxyurea in the Pediatric Hematology Unit.
Contacts and Locations| Israel | |
| Pediatric Hematology Unit - HaEmek Medical Center | |
| Afula, Israel, 18101 | |
| Study Director: | Ariel Koren, MD | Pediatric Hematology Unit, Ha'Emek Medical Center |
| Study Chair: | Carina Levin, MD | Pediatric Hematology Unit - Ha'Emek Medical Center |
| Principal Investigator: | Miri Golan, Student | Pediatric Hematology Unit - HaEmek Medical Center |
| Study Chair: | Luci Zalman, PhD | Hematology Laboratory - HaEmek Medical Center |
More Information
No publications provided
| Responsible Party: | Dr Koren Ariel, Pediatric Hematology Unit - HaEmek Medical Center - Afula - Israel |
| ClinicalTrials.gov Identifier: | NCT00480974 History of Changes |
| Other Study ID Numbers: | 5321006.EMC |
| Study First Received: | May 31, 2007 |
| Last Updated: | September 3, 2009 |
| Health Authority: | Israel: Ministry of Health |
Keywords provided by HaEmek Medical Center, Israel:
|
Sickle cell anemia Sickle cell thalassemia Hydroxyurea |
Additional relevant MeSH terms:
|
Anemia Anemia, Sickle Cell Thalassemia Hematologic Diseases Anemia, Hemolytic, Congenital Anemia, Hemolytic Hemoglobinopathies Genetic Diseases, Inborn Hydroxyurea |
Antineoplastic Agents Therapeutic Uses Pharmacologic Actions Antisickling Agents Hematologic Agents Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Nucleic Acid Synthesis Inhibitors |
ClinicalTrials.gov processed this record on May 21, 2013